FATE News and Press, Fate Therapeutics Inc. From 03/15/21

Fate Therapeutics, an immuno-oncology biopharmaceutical company, has novel core technology with the potential to become a strong competitor in the sector. The company's iPSC-based NK-cell and T-cell immunotherapies are at the forefront of innovation in one of science's most cutting-ed...

This investment strategy holds a maximum of 50 consensus stock picks from 40 hedge funds with more than $3,500 million Assets Under Management. Changes in the holdings occur only every three months when the end of the quarter 13F filings become public information; the latest date was ...

The analysts at Bank of America have initiated the coverage on Fate Therapeutics ([[FATE]] +3.7%) with a buy rating and a price target of $115.00 per share indicating an upside of ~33.3%.As the diagram shows below, early-stage candidates dominate the company’s pipeline which prima...

Fate Therapeutics (FATE) initiated with a Buy at BofA Securities. PT set to $115, implies a 33% increase from last price.Wedbush analyst David Nierengarten downgraded FATE to Neutral from Outperform as it sees “higher downside risk”and less reward as clinical programs advance an...

Image source: The Motley Fool. Fate Therapeutics Inc (NASDAQ: FATE) Q4 2020 Earnings Call Feb 24, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: Fate Therapeutics Inc (FATE) Q4 2020 Earnings Call Transcript

Fate Therapeutics, Inc. (FATE) Q4 2020 Earnings Conference Call February 24, 2021 17:00 ET Corporate Participants Scott Wolchko - President and Chief Executive Officer Ed Dulac - Chief Financial Officer Bob Valamehr - Chief Development Officer Wayne Chu - Senior Vice President, Clinical Devel...

Fate Therapeutics (FATE): Q4 GAAP EPS of -$0.61 misses by $0.22.Revenue of $15.9M (+467.9% Y/Y) beats by $10.85M.Press Release For further details see: Fate Therapeutics EPS misses by $0.22, beats on revenue

Positive Interim Data Reported from FT516 Phase 1 Study in Relapsed / Refractory BCL; Objective Responses, including Two Complete Responses, Achieved in 3 of 4 Patients in Dose Cohorts 2 and 3 Clinical Activity of FT596 as Monotherapy Demonstrated in Refractory DLBCL; Partial Re...

[[ACA]], [[ACAD]], [[ADPT]], [[AGI]], [[AMED]], [[ANSS]], [[APA]], [[AWK]], [[BILI]], [[BKNG]], [[CCRN]], [[CDNA]], [[CHDN]], [[CNXN]], [[CW]], [[DDD]], [[DOOR]], [[DRH]], [[ECPG]], [[EPR]], [[ESI]], [[ESTC]], [[FATE]], [[FNF]], [[FTI]], [[GBT]], [[GEF]], [[GH]], [[HCC]], [[ICLR]], [[INGN]], ...

Fate Therapeutics (NASDAQ:FATE) is scheduled to announce Q4 earnings results on Wednesday, February 24th, after market close.The consensus EPS Estimate is -$0.38 (-2.7% Y/Y) and the consensus Revenue Estimate is $5.05M (+80.4% Y/Y).Over the last 1 year, FATE has beaten EPS estimates 25% of th...